Heterocyclic GLP-1 agonists
This disclosure relates to GLP-1 agonists of Formula I: including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
1. A compound of Formula (I-A4-1), or a pharmaceutically acceptable salt thereof:
wherein:
is a single bond or a double bond;
R 0-1 is selected from the group consisting of hydrogen and (C 1 -C 3 )alkyl;
X 4 is selected from the group consisting of N and CR y ;
R y is selected from the group consisting of hydrogen, —OH, (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )haloalkoxy, CN, and halogen;
T 2 is (C 1 -C 3 )alkyl which is substituted with a substituent selected from the group consisting of (C 1 -C 3 )alkoxy, S(O) 2 (C 1 -C 3 alkyl), (C 3 -C 6 )cycloalkyl, 3- to 6-membered heterocycloalkyl, phenyl, and 5- to 6-membered heteroaryl, wherein the phenyl or 5- to 6-membered heteroaryl are each optionally substituted with halogen or (C 1 -C 3 )alkyl;
R aa is selected from the group consisting of hydrogen and (C 1 -C 3 )alkyl;
Ring C is selected from the group consisting of phenyl and 6-membered heteroaryl;
b is 0, 1, or 2; and
each occurrence of R b is independently selected from the group consisting of (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )haloalkoxy, halogen, and CN.
2. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is selected from the group consisting of:
3. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
4. The compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is:
5. The compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is: